Advertisement
ABBV or JNJ or MRK
Which Stock Would AI Choose? AbbVie (ABBV) vs. Johnson & Johnson (JNJ) vs. Merck (MRK) Stock Comparison
Key Takeaways
- AbbVie (ABBV) is successfully replacing declining Humira sales with its Skyrizi and Rinvoq immunology franchise, supported by low stock volatility and a steady dividend.
- Johnson & Johnson (JNJ) combines strong pharmaceutical growth with a softer medical-device (MedTech) segment, while talc litigation remains a lingering overhang.
- Merck (MRK) has delivered the strongest recent share-price momentum but trades at a much richer valuation as investors bet on its post-Keytruda pipeline.
- All three are large-cap healthcare leaders, but they differ sharply in business mix, growth drivers, valuation, and risk profile.
- ABBV skews defensive and income-oriented; JNJ is diversified but facing execution questions; MRK offers higher growth potential at higher valuation risk.
Introduction
AbbVie Inc., Johnson & Johnson, and Merck & Co., Inc. are three of the largest names in global healthcare, yet their investment profiles are far from interchangeable. This stock comparison examines how each company is positioned across business model, recent momentum, and market sentiment. For investors weighing defensive dividend income against higher-growth pipeline optionality, the contrast is instructive. Traders monitoring relative performance will also find meaningful differences: one stock has been climbing on execution, another on diversification, and a third on aggressive pipeline optimism. Understanding these trade-offs helps clarify which name might suit a given market environment and risk tolerance.
ABBV Overview and Recent Performance
ABBV is a research-based biopharmaceutical company best known for its immunology franchise. In recent quarters the narrative has centered on its next-generation medicines, Skyrizi and Rinvoq, whose combined growth has more than offset the long-anticipated erosion of Humira following its loss of exclusivity (LOE, the expiry of patent protection). Recent market activity reflects growing confidence that this transition is working: the company raised its full-year revenue outlook, while immunology and neuroscience segments posted double-digit operational growth. Investor sentiment has also been shaped by the planned acquisition of Apogee Therapeutics, which modestly trimmed near-term earnings guidance but extends the pipeline. With a low beta (a measure of sensitivity to broader market swings) and a dividend yield near 2.5%, ABBV has behaved more like a defensive compounder than a volatile growth name.
JNJ Overview and Recent Performance
JNJ operates as a diversified healthcare company across two segments: Innovative Medicine (pharmaceuticals) and MedTech (medical devices). Recent results show a two-speed business. Its pharmaceutical arm has been a clear strength, led by strong growth from Tremfya, Darzalex, Spravato, and Caplyta, which are offsetting the decline of Stelara after it lost exclusivity. By contrast, the MedTech segment has decelerated, pressured by China pricing, European healthcare austerity, Middle East disruption, and softer cardiovascular demand. A large pre-tax charge tied to a proposed talc litigation settlement also weighed on reported earnings. Despite raising full-year guidance, the stock pulled back after its most recent earnings release, underscoring how execution concerns in MedTech have tempered an otherwise strong rally over the past year.
MRK Overview and Recent Performance
MRK is an oncology-led pharmaceutical and vaccines company whose fortunes remain closely tied to Keytruda, its flagship cancer immunotherapy. Recent market activity has been notably strong, with shares reaching a 52-week high on positive late-stage data from a personalized mRNA cancer vaccine program conducted with Moderna, plus a series of pipeline milestones and acquisitions. Newer products such as Winrevair, Capvaxive, and Lipfendra are scaling, and management points to more than $70 billion in potential pipeline revenue by the mid-2030s as Keytruda approaches its 2028 LOE. However, this momentum comes with caveats: a Dutch court injunction on a subcutaneous Keytruda formulation added legal uncertainty in Europe, and acquisition-related charges have distorted earnings. The result is strong share-price performance paired with a premium valuation that leaves less margin for error.
Trending AI Robots
For investors seeking a data-driven approach to names like these, Tickeron's Trending AI Robots page offers a curated view of its AI trading bots. Tickeron hosts hundreds of AI trading bots that collectively trade thousands of different tickers, each built around a distinct trading style, strategy, timeframe, and set of performance statistics. Rather than listing every available bot, the Trending AI Robots section highlights only those deemed best suited to current market conditions. This focused selection lets users compare bots by performance, volatility, and traded tickers, making it easier to identify strategies aligned with today's environment. Explore the Trending AI Robots page to see which strategies are currently leading.
Head-to-Head Comparison
The three companies diverge most clearly on business mix and growth drivers. ABBV is an immunology specialist with meaningful aesthetics, neuroscience, and oncology exposure, balancing growth with a defensive profile. JNJ is the most diversified, spanning pharmaceuticals and medical devices, which historically smooths earnings but currently drags on momentum. MRK is the most concentrated around a single franchise, Keytruda, making its story heavily dependent on successful pipeline diversification.
On valuation, the gap is wide. MRK trades at a substantial premium to the large-cap pharmaceutical industry on both trailing and forward earnings, reflecting investors paying up for future growth. ABBV carries a moderate forward multiple and an attractive dividend, while JNJ sits between the two, with a recent re-rating that has narrowed its margin of safety. In terms of recent relative performance, MRK has led, followed by a steady ABBV, while JNJ's advance has been partially reversed by MedTech concerns and litigation overhangs. Risk factors also differ: ABBV faces competitive pressure in immunology, JNJ confronts device-segment execution and legal liabilities, and MRK carries concentration and valuation risk ahead of its 2028 patent cliff.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely favor the stock with the most consistent combination of trend strength, catalyst clarity, and manageable valuation risk. MRK currently displays the strongest recent trend and catalyst pipeline, but its premium valuation and concentration risk introduce greater sensitivity to disappointment. JNJ offers diversification yet is burdened by device-segment softness and litigation. On balance, ABBV appears to present the most balanced profile: consistent execution in replacing a legacy blockbuster, low volatility, steady income, and multiple growth franchises. Accordingly, an AI model weighting trend consistency, stability, and relative positioning would probably lean toward ABBV as the more favorable near-to-medium-term candidate, while acknowledging MRK's higher momentum and JNJ's diversification as meaningful trade-offs.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ABBV's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for ABBV turned positive on October 07, 2026. Looking at past instances where ABBV's MACD turned positive, the stock continued to rise in 33 of 46 cases over the following month. The odds of a continued upward trend are 72%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 05, 2026. You may want to consider a long position or call options on ABBV as a result. In 54 of 77 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 70%.
Following a +0.29% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABBV advanced for three days, in 218 of 359 cases, the price rose further within the following month. The odds of a continued upward trend are 61%.
The Aroon Indicator entered an Uptrend today. In 220 of 355 cases where ABBV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 62%.
Bearish Trend Analysis
The 10-day RSI Indicator for ABBV moved out of overbought territory on October 21, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 45 similar instances where the indicator moved out of overbought territory. In 17 of the 45 cases, the stock moved lower in the following days. This puts the odds of a move lower at 38%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 12 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABBV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 46%.
ABBV broke above its upper Bollinger Band on October 07, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 1 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 3 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ABBV's P/B Ratio (-85.048) is very low in comparison to the industry average of (-2.730). ABBV has a moderately high P/E Ratio (80.689) as compared to the industry average of (21.349). Projected Growth (PEG Ratio) (0.544) is also within normal values, averaging (5.738). Dividend Yield (0.024) settles around the average of (0.040) among similar stocks. ABBV's P/S Ratio (7.231) is slightly higher than the industry average of (4.033).
The Tickeron Profit vs. Risk Rating rating for this company is 3 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 14 (best 1 - 100 worst), indicating outstanding price growth. ABBV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 74 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
JNJ's RSI Oscillator climbs out of oversold territory
The RSI Indicator for JNJ moved out of oversold territory on October 07, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 30 similar instances when the indicator left oversold territory. In 14 of the 30 cases the stock moved higher. This puts the odds of a move higher at 47%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on JNJ as a result. In 39 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 46%.
The Moving Average Convergence Divergence (MACD) for JNJ just turned positive on October 21, 2026. Looking at past instances where JNJ's MACD turned positive, the stock continued to rise in 21 of 47 cases over the following month. The odds of a continued upward trend are 45%.
Following a +2.83% 3-day Advance, the price is estimated to grow further. Considering data from situations where JNJ advanced for three days, in 164 of 354 cases, the price rose further within the following month. The odds of a continued upward trend are 46%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
JNJ moved below its 50-day moving average on October 23, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for JNJ crossed bearishly below the 50-day moving average on October 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 59%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JNJ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 40%.
JNJ broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for JNJ entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 4 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 37 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. JNJ’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.482) is normal, around the industry mean (-2.730). P/E Ratio (30.219) is within average values for comparable stocks, (21.349). Projected Growth (PEG Ratio) (2.852) is also within normal values, averaging (5.738). Dividend Yield (0.020) settles around the average of (0.040) among similar stocks. P/S Ratio (6.658) is also within normal values, averaging (4.033).
MRK sees its Stochastic Oscillator climbs out of oversold territory
On October 09, 2026, the Stochastic Oscillator for MRK moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 52 instances where the indicator left the oversold zone. In 33 of the 52 cases the stock moved higher in the following days. This puts the odds of a move higher at over 63%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for MRK just turned positive on October 20, 2026. Looking at past instances where MRK's MACD turned positive, the stock continued to rise in 27 of 51 cases over the following month. The odds of a continued upward trend are 53%.
Following a +4.35% 3-day Advance, the price is estimated to grow further. Considering data from situations where MRK advanced for three days, in 192 of 339 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.
MRK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 23, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MRK as a result. In 47 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 55%.
MRK moved below its 50-day moving average on October 23, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for MRK crossed bearishly below the 50-day moving average on October 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 56%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 51%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 29 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. MRK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 79 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 89 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.547) is normal, around the industry mean (-2.730). MRK's P/E Ratio (115.294) is considerably higher than the industry average of (21.349). Projected Growth (PEG Ratio) (2.716) is also within normal values, averaging (5.738). Dividend Yield (0.023) settles around the average of (0.040) among similar stocks. P/S Ratio (5.402) is also within normal values, averaging (4.033).
ABBV | JNJ | MRK | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 45 | 73 | 75 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 3 Undervalued | 77 Overvalued | 89 Overvalued | |
PROFIT vs RISK RATING 1..100 | 3 | 4 | 29 | |
SMR RATING 1..100 | 1 | 37 | 79 | |
PRICE GROWTH RATING 1..100 | 14 | 43 | 39 | |
P/E GROWTH RATING 1..100 | 74 | 7 | 1 | |
SEASONALITY SCORE 1..100 | 50 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ABBV's Valuation (3) in the Pharmaceuticals Major industry is significantly better than the same rating for JNJ (77) and is significantly better than the same rating for MRK (89). This means that ABBV's stock grew significantly faster than JNJ’s and significantly faster than MRK’s over the last 12 months.
ABBV's Profit vs Risk Rating (3) in the Pharmaceuticals Major industry is in the same range as JNJ (4) and is in the same range as MRK (29). This means that ABBV's stock grew similarly to JNJ’s and similarly to MRK’s over the last 12 months.
ABBV's SMR Rating (1) in the Pharmaceuticals Major industry is somewhat better than the same rating for JNJ (37) and is significantly better than the same rating for MRK (79). This means that ABBV's stock grew somewhat faster than JNJ’s and significantly faster than MRK’s over the last 12 months.
ABBV's Price Growth Rating (14) in the Pharmaceuticals Major industry is in the same range as MRK (39) and is in the same range as JNJ (43). This means that ABBV's stock grew similarly to MRK’s and similarly to JNJ’s over the last 12 months.
MRK's P/E Growth Rating (1) in the Pharmaceuticals Major industry is in the same range as JNJ (7) and is significantly better than the same rating for ABBV (74). This means that MRK's stock grew similarly to JNJ’s and significantly faster than ABBV’s over the last 12 months.
| ABBV | JNJ | MRK | |
|---|---|---|---|
| RSI ODDS (%) | 1 day ago 38% | 1 day ago 47% | N/A |
| Stochastic ODDS (%) | 1 day ago 38% | 1 day ago 48% | 1 day ago 63% |
| Momentum ODDS (%) | 1 day ago 70% | 1 day ago 46% | 1 day ago 55% |
| MACD ODDS (%) | 1 day ago 72% | 1 day ago 45% | 1 day ago 53% |
| TrendWeek ODDS (%) | 1 day ago 63% | 1 day ago 47% | 1 day ago 49% |
| TrendMonth ODDS (%) | 1 day ago 64% | 1 day ago 45% | 1 day ago 42% |
| Advances ODDS (%) | 1 day ago 61% | 13 days ago 46% | 4 days ago 57% |
| Declines ODDS (%) | 24 days ago 46% | 20 days ago 40% | 1 day ago 51% |
| BollingerBands ODDS (%) | 1 day ago 40% | 1 day ago 31% | 1 day ago 60% |
| Aroon ODDS (%) | 1 day ago 62% | 1 day ago 38% | N/A |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABBV’s FA Score shows that 4 FA rating(s) are green while JNJ’s FA Score has 2 green FA rating(s), and MRK’s FA Score reflects 2 green FA rating(s).
- ABBV’s FA Score: 4 green, 1 red.
- JNJ’s FA Score: 2 green, 3 red.
- MRK’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABBV’s TA Score shows that 4 TA indicator(s) are bullish while JNJ’s TA Score has 4 bullish TA indicator(s), and MRK’s TA Score reflects 4 bullish TA indicator(s).
- ABBV’s TA Score: 4 bullish, 4 bearish.
- JNJ’s TA Score: 4 bullish, 6 bearish.
- MRK’s TA Score: 4 bullish, 4 bearish.
Price Growth
ABBV (@Pharmaceuticals: Major) experienced а +0.08% price change this week, while JNJ (@Pharmaceuticals: Major) price change was +3.23% , and MRK (@Pharmaceuticals: Major) price fluctuated -0.47% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.08%. For the same industry, the average monthly price growth was -4.91%, and the average quarterly price growth was +4.21%.
Reported Earning Dates
ABBV is expected to report earnings on Oct 30, 2026.
JNJ is expected to report earnings on Jan 26, 2027.
MRK is expected to report earnings on Oct 29, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-0.08% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
ABBV and
Correlation & Price change
A.I.dvisor indicates that over the last year, ABBV has been loosely correlated with NVS. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if ABBV jumps, then NVS could also see price increases.
| Ticker / NAME | Correlation To ABBV | 1D Price Change % | ||
|---|---|---|---|---|
| ABBV | 100% | +0.16% | ||
| NVS - ABBV | 50% Loosely correlated | -3.30% | ||
| JNJ - ABBV | 49% Loosely correlated | -1.42% | ||
| AMGN - ABBV | 48% Loosely correlated | -1.79% | ||
| BMY - ABBV | 47% Loosely correlated | -2.41% | ||
| BIIB - ABBV | 41% Loosely correlated | -1.24% | ||
More | ||||
JNJ and
Correlation & Price change
A.I.dvisor indicates that over the last year, JNJ has been loosely correlated with ABBV. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if JNJ jumps, then ABBV could also see price increases.
MRK and
Correlation & Price change
A.I.dvisor indicates that over the last year, MRK has been loosely correlated with GSK. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if MRK jumps, then GSK could also see price increases.